Development of Immunotherapy Combination Strategies in Cancer
Open accessThe DOI matches its Crossref record; 255 of the 255 references it cites were found in a registry or an index.
Abstract
Harnessing the immune system to treat cancer through inhibitors of CTLA4 and PD-L1 has revolutionized the landscape of cancer. Rational combination strategies aim to enhance the antitumor effects of immunotherapies, but require a deep understanding of the mechanistic underpinnings of the immune system and robust preclinical and clinical drug development strategies. We review the current approved immunotherapy combinations, before discussing promising combinatorial approaches in clinical trials and detailing innovative preclinical model systems being used to develop rational combinations. We also discuss the promise of high-order immunotherapy combinations, as well as novel biomarker and combinatorial trial strategies.Significance: Although immune-checkpoint inhibitors are approved as dual checkpoint strategies, and in combination with cytotoxic chemotherapy and angiogenesis inhibitors for multiple cancers, patient benefit remains limited. Innovative approaches are required to guide the development of novel immunotherapy combinations, ranging from improvements in preclinical tumor model systems to biomarker-driven trial strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 10×
“Scientific Reports 2019;9(1):11472 doi 10.”
BackgroundInfluentialMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 6×
“N Engl J Med 2019;380(12):1103–15 doi 10.”
BackgroundInfluentialPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 3×
“been successful in non-small cell lung cancer (22), with the immunogenic response generated by chemotherapy overcoming the lower response rates observed with anti-PD-1 treatment alone in low PD-L1 expressing tumors (31).”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Research works printed but not linked: 16
- Davar D, 2018, A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma, J Immunother Cancer, 6, O21
- Lakhani N, 2018, The anti–LAG-3 antibody MK-4280 as monotherapy and in combination with pembrolizumab for advanced solid tumors: first-in-human phase 1 dose-finding study, J Immunother cancer, O114
- Weber, 2018, 1304TiP - A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM), Ann Oncol, 29, viii465, 10.1093/annonc/mdy289.060 · doi:10.1093/annonc/mdy289.060
- Hickingbottom, 2020, Preliminary safety and pharmacodynamic (PD) activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in a phase I dose escalation study of patients with selected advanced solid tumors, J Clin Oncol, 38, e15001, 10.1200/JCO.2020.38.15_suppl.e15001 · doi:10.1200/jco.2020.38.15_suppl.e15001
- Langowski, 2016, Abstract B057: the CD122-biased immunostimulatory cytokine NKTR-214 combined with checkpoint blockade leads to mobilization of antitumor immunity and synergistic activity, Cancer Immunol Res, 4, B057, 10.1158/2326-6066.IMM2016-B057 · doi:10.1158/2326-6066.imm2016-b057
- Zappasodi, 2019, Abstract PR01: mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients, Cancer Immunol Res, 7, PR01, 10.1158/2326-6074.CRICIMTEATIAACR18-PR01 · doi:10.1158/2326-6074.cricimteatiaacr18-pr01
- Reilley, 2019, Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors, J Clin Oncol, 37, TPS2669, 10.1200/JCO.2019.37.15_suppl.TPS2669 · doi:10.1200/jco.2019.37.15_suppl.tps2669
- Diab, 2018, 1245PD – Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): results from a multicenter, phase I/II study, Ann Oncol, 29, viii442, 10.1093/annonc/mdy289.001 · doi:10.1093/annonc/mdy289.001
- Komatsu, 2017, Abscopal effect of nivolumab in a patient with primary lung cancer, J Thorac Oncol, 12, e143, 10.1016/j.jtho.2017.05.004 · doi:10.1016/j.jtho.2017.05.004
- Zhang, 2018, ATMJAKPDL1 signaling pathway inhibition decreases EMT and metastasis of androgenindependent prostate cancer, Mol Med Rep, 17, 7045
- Ørskov, 2017, Activation of T cells specific to endogenous retroviral peptides: possible association with clinical response to azacitidine in myeloid malignancies, Blood, 130, 4243
- Alvarez, 2011, B16 murine melanoma: historical perspective on the development of a solid tumor model, 79, 10.1007/978-1-60761-968-0_4 · doi:10.1007/978-1-60761-968-0_4
- Gajewski, 2001, The p815 mastocytoma tumor model, Curr Protoc Immunol, 10.1002/0471142735.im2004s43 · doi:10.1002/0471142735.im2004s43
- Huang, 2018, Abstract A207: utilizing human OX40 knock-in mice (HuGEMMTM) to assess antitumor efficacy of OX40-agonistic antibodies, Mol Cancer Ther, 17, A207, 10.1158/1535-7163.TARG-17-A207 · doi:10.1158/1535-7163.targ-17-a207
- Zheng, 2018, Abstract A203: generation of human TIM3 knock-in mice for preclinical efficacy assessment of therapeutic antibodies, Mol Cancer Ther, 17, A203, 10.1158/1535-7163.TARG-17-A203 · doi:10.1158/1535-7163.targ-17-a203
- Food and Drug Administration H, 2020, Cancer clinical trial eligibility criteria: brain metastases guidance for industry, Fed Regist, 85, 41992
Cited by
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Immunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Yi, M., Niu, M., Zhang, J., Li, S., Zhu, S., Yan, Y., Li, N., Zhou, P., Chu, Q., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01155-6 · Cited by 163
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
Metadata
- Authors
- Yap, T. A., Parkes, E. E., Peng, W., Moyers, J. T., Curran, M. A., & Tawbi, H. A.
- Venue
- Cancer Discovery
- Published
- 2021-04-02
- Volume
- 11
- Issue
- 6
- Pages
- 1368-1397
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3141168022
- Cited by
- 330
- References
- 255
- FWCI
- 17.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.